Research Papers:
Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3
Metrics: PDF 4957 views | HTML 5660 views | ?
Abstract
Shicong Zhu1,*, Zhihua Wang1,*, Zijian Li1,2, Hongling Peng1, Yunya Luo1, Mingyang Deng1, Ruijuan Li1, Chongwen Dai1, Yunxiao Xu1, Sufang Liu1, Guangsen Zhang1
1Division of Hematology, Institute of Molecular Hematology, The Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China
2Division of Hematology, The First Affiliated Hospital, Lanzhou University, Lanzhou, Gansu, China
*These authors have contributed equally to this work
Corresponding to:
Guangsen Zhang, e-mail: [email protected]
Keywords: icaritin, multiple myeloma, antitumor activities, IL6/JAK2/STAT3 signaling
Received: January 19, 2015 Accepted: February 15, 2015 Published: March 16, 2015
ABSTRACT
Icaritin is an active prenylflavonoid derived from Epimedium genus, a traditional Chinese medicine. Icaritin has a wide range of pharmacological and biological activities, including cardiovascular function improvement, hormone regulation and antitumor activity. Here, we investigated the effect of icaritin on multiple myeloma (MM) in vitro and in vivo. Icaritin inhibited cell growth of MM cell line and primary MM cells. In contrast, icaritin had low or no cytotoxic effect on normal hematopoiesis. We also demonstrated that in MM xenograft mouse models, icaritin suppressed tumor growth and decreased serum IL-6 and IgE levels, but did not show adverse reactions such as body weight loss. The anti-MM activity of icaritin was mainly mediated by inhibiting IL-6/JAK2/STAT3 signaling. We suggest that icaritin can be further tested in clinical trials in MM.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3399